S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Is this AI's biggest breakthrough to date? (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Is this AI's biggest breakthrough to date? (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Is this AI's biggest breakthrough to date? (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Is this AI's biggest breakthrough to date? (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:HOOK

Hookipa Pharma (HOOK) Stock Price, News & Analysis

$0.64
-0.02 (-3.03%)
(As of 02/23/2024 ET)
Today's Range
$0.61
$0.66
50-Day Range
$0.56
$0.86
52-Week Range
$0.41
$2.05
Volume
733,644 shs
Average Volume
585,217 shs
Market Capitalization
$53.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.17

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
707.2% Upside
$5.17 Price Target
Short Interest
Healthy
0.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

356th out of 941 stocks

Pharmaceutical Preparations Industry

159th out of 432 stocks


HOOK stock logo

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

HOOK Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Hookipa Pharma Inc (HOOK)
HOOKIPA Pharma To Cut Jobs Following Collaboration Termination By Roche
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
HOOKIPA Pharma Inc. (HOOK)
Why Is Hookipa Pharma (HOOK) Stock Up 81% Today?
HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/23/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.17
High Stock Price Target
$6.50
Low Stock Price Target
$4.00
Potential Upside/Downside
+707.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-64,920,000.00
Net Margins
-336.12%
Pretax Margin
-334.01%

Debt

Sales & Book Value

Annual Sales
$14.25 million
Book Value
$1.87 per share

Miscellaneous

Free Float
79,064,000
Market Cap
$53.74 million
Optionable
Optionable
Beta
0.98
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price target for 2024?

3 Wall Street research analysts have issued 12-month price objectives for Hookipa Pharma's stock. Their HOOK share price targets range from $4.00 to $6.50. On average, they expect the company's stock price to reach $5.17 in the next twelve months. This suggests a possible upside of 707.2% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2024?

Hookipa Pharma's stock was trading at $0.81 at the beginning of 2024. Since then, HOOK shares have decreased by 21.0% and is now trading at $0.6401.
View the best growth stocks for 2024 here
.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 446,100 shares, a decline of 28.1% from the January 15th total of 620,200 shares. Based on an average daily trading volume, of 2,420,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.8% of the shares of the stock are short sold.
View Hookipa Pharma's Short Interest
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.09. The firm earned $3.87 million during the quarter, compared to analysts' expectations of $5.24 million. Hookipa Pharma had a negative net margin of 336.12% and a negative trailing twelve-month return on equity of 70.24%. During the same quarter in the previous year, the firm earned ($0.53) EPS.

What other stocks do shareholders of Hookipa Pharma own?
When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Royal Bank of Canada (0.26%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr.
View institutional ownership trends
.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 2/24/2024 by MarketBeat.com Staff